Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Injects $2M into SynapDx for Autism Test Development

NEW YORK (GenomeWeb News) – Laboratory Corporation of America is investing $2 million in SynapDx to further its development of an autism spectrum disorder test.

The investment, announced today by SynapDx, follows a $6 million Series A1 funding round completed in December to support the Lexington, Mass.-based firm's clinical study in support of the ASD test, which is intended to help physicians identify children with ASD earlier than they can today.

The test would be the first step in SynapDx's plans to build a broader menu of pediatric neurodevelopment tests, the company said.

"LabCorp and SynapDx have a shared vision about the future of diagnostics," SynapDx CEO Stanley Lapidus said in a statement. "The investment is validation of LabCorp's commitment to innovation and SynapDx's transformational approach to autism diagnostics."

SynapDx's blood-based test is being developed to measure RNA expression in order to differentiate children with a higher risk for ASDs from those with a lower risk. Its aim is to identify children with ASD by the age of 36 months.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.